Hematopoietic Cell Transplantation for Lymphomas (Q37942817)

25 August 2017

1 reference

title

Hematopoietic cell transplantation for lymphomas (English)

1 reference

25 August 2017

Hematopoietic Cell Transplantation for Lymphomas (English)

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

13 December 2024

author name string

Ernesto Ayala

1

1 reference

25 August 2017

Marcie Tomblyn

2

1 reference

25 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21976243

13 December 2024

publication date

1 October 2011

1 reference

25 August 2017

October 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21976243

13 December 2024

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

246-257

1 reference

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Cancer risk in people infected with human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Could bone marrow transplantation cure AIDS?: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

How I treat mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

State-of-the-art therapeutics: Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800405

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

13 December 2024

3

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

13 December 2024

25

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Reg

13 December 2024

29

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

13 December 2024

31

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

13 December 2024

34

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of

13 December 2024

35

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

13 December 2024

38

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

13 December 2024

39

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

13 December 2024

42

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Autologous stem-cell transplantation in patients with HIV-related lymphoma

13 December 2024

51

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma

13 December 2024

56

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma

13 December 2024

57

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience

13 December 2024

58

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

13 December 2024

61

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

13 December 2024

62

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma

13 December 2024

67

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy

13 December 2024

68

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

13 December 2024

87

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

13 December 2024

88

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

13 December 2024

97

1 reference

https://api.crossref.org/works/10.1177/107327481101800405

13 December 2024

Identifiers

0 references

1 reference